Rossari Biotech

Which are the latest news on Rossari Biotech?

Why is Rossari Biotech Ltd falling/rising?

As of 05-Sep, Rossari Biotech Ltd's stock price is rising to 460.90, indicating a potential shift in market sentiment after a decline. Despite this short-term increase, the stock remains below its moving averages and faces longer-term challenges, including negative quarterly results and decreased institutional participation.

As of 05-Sep, Rossari Biotech Ltd's stock price is rising, currently at 460.90, with a change of 3.95 (0.86%) upward. This increase follows a trend reversal after seven consecutive days of decline, indicating a potential shift in market sentiment. The stock outperformed its sector by 0.9% today and reached an intraday high of Rs 466.4, reflecting positive trading activity.<BR><BR>Additionally, there has been a significant rise in investor participation, with delivery volume on 03 Sep increasing by 397.93% compared to the five-day average. This suggests renewed interest from investors, which may contribute to the stock's upward movement. However, it is important to note that despite today's rise, the stock is still trading below its moving averages across various time frames, indicating that it may still be in a longer-term downtrend.<BR><BR>While the company has reported negative results for the last three consecutive quarters and has seen a decrease in institutional investor participation, the current rise in stock price could be attributed to short-term trading dynamics rather than a fundamental turnaround. Overall, the stock's recent performance reflects a complex situation where short-term gains are occurring amidst a backdrop of longer-term challenges.

Who are in the management team of Rossari Biotech?

The management team of Rossari Biotech includes Sunil Chari (Managing Director), Edward Menezes (Chairman & Executive Director), and several independent directors, along with Parul Gupta (Company Secretary) and Esha Padmanabhan Achan (Additional Director), who collectively guide the company's strategic direction and ensure regulatory compliance.

The management team of Rossari Biotech includes the following key members:<BR><BR>1. **Sunil Chari** - Managing Director<BR>2. **Edward Menezes** - Chairman & Executive Director<BR>3. **Goutam Bhattacharya** - Non-Executive & Independent Director<BR>4. **Aseem Dhru** - Non-Executive & Independent Director<BR>5. **Sharabh Pachory** - Non-Executive & Independent Director<BR>6. **Parul Gupta** - Company Secretary & Compliance Officer<BR>7. **Aparna Narendra Sharma** - Additional Independent Director<BR>8. **Esha Padmanabhan Achan** - Additional Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

What does Rossari Biotech do?

Rossari Biotech Ltd is a small-cap company in the specialty chemicals industry, founded in 2003 and converted to a limited company in 2009. As of June 2026, it reported net sales of 697 Cr and a net profit of 35 Cr, with a market cap of INR 2,731 Cr.

Overview:<BR>Rossari Biotech Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History:<BR>Founded in 2003 as a partnership firm named Rossari Labtech, the company was established by Mr. Edward Walter Menezes and Mr. Sunil Srinivasan Chari. It was renamed Rossari Biotech Limited and converted into a company in 2009. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 697 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 35 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 2,731 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 18.00 <BR>Industry P/E: 43 <BR>Dividend Yield: 0.10% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 11.19% <BR>Price to Book: 2.07 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Rossari Biotech?

Peers of Rossari Biotech include Styrenix Perfor., Jubilant Agri, Bhansali Engg., DDev Plastiks, NOCIL, S H Kelkar & Co., Camlin Fine, Paushak, and Vidhi Specialty. Rossari Biotech has average growth and management risk, with a 1-year return of -21.47%.

Peers: The peers of Rossari Biotech are Styrenix Perfor., Jubilant Agri, Bhansali Engg., DDev Plastiks, NOCIL, S H Kelkar & Co., Camlin Fine, Paushak, and Vidhi Specialty.<BR><BR>Quality Snapshot: Excellent management risk is observed at Styrenix Perfor. and Rossari Biotech, while Average management risk is found at Jubilant Agri, Bhansali Engg., DDev Plastiks, NOCIL, S H Kelkar & Co., Paushak, and Vidhi Specialty, and Below Average management risk is noted at Camlin Fine. Growth is Excellent at Jubilant Agri, Good at DDev Plastiks, Average at Rossari Biotech, and Below Average at Styrenix Perfor., Bhansali Engg., NOCIL, S H Kelkar & Co., Camlin Fine, Paushak, and Vidhi Specialty. Capital Structure is Excellent at Styrenix Perfor., Jubilant Agri, Bhansali Engg., DDev Plastiks, NOCIL, Paushak, and Vidhi Specialty, Average at S H Kelkar & Co., and Below Average at Camlin Fine.<BR><BR>Return Snapshot: Jubilant Agri has the highest 1-year return at -19.77%, while Camlin Fine has the lowest at -49.11%, with Rossari Biotech's 1-year return at -21.47%, which is better than Camlin Fine but worse than Jubilant Agri. Additionally, S H Kelkar & Co. and Camlin Fine have negative six-month returns.

How big is Rossari Biotech?

As of 31st August, Rossari Biotech Ltd has a market capitalization of 2,731.00 Cr, with recent net sales of 2,549.85 Cr and a net profit of 150.72 Cr. The company reported shareholder's funds of 1,333.35 Cr and total assets of 2,273.85 Cr for the latest annual period ending in March 2026.

As of 31st August, Rossari Biotech Ltd has a market capitalization of 2,731.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Rossari Biotech reported Net Sales of 2,549.85 Cr and a Net Profit of 150.72 Cr.<BR><BR>For the latest annual period ending in March 2026, the company had Shareholder's Funds amounting to 1,333.35 Cr and Total Assets of 2,273.85 Cr.

Are Rossari Biotech Ltd latest results good or bad?

Rossari Biotech Ltd's latest results show strong revenue growth with record net sales of ₹697.20 crores, but a significant decline in net profit to ₹35.10 crores raises concerns about operational efficiency and profitability, suggesting investors should proceed with caution.

Rossari Biotech Ltd's latest results present a mixed picture. On one hand, the company achieved record net sales of ₹697.20 crores, reflecting a strong year-on-year growth of 28.23% and a slight quarter-on-quarter increase of 1.80%. This indicates robust demand and market positioning.<BR><BR>However, the bottom line tells a different story. The net profit for the quarter fell to ₹35.10 crores, which is a significant decline of 23.65% compared to the previous quarter, despite a modest year-on-year increase of 4.46%. This sharp drop raises concerns about the company's operational efficiency and cost management, particularly in light of rising interest costs and depreciation charges.<BR><BR>Moreover, the operating margin improved slightly to 11.56% from the previous quarter but is down from 12.48% a year ago. The PAT margin also contracted to 5.03%, indicating profitability pressures.<BR><BR>Overall, while the revenue growth is impressive, the significant decline in net profit and margin compression suggest underlying challenges that could affect the company's financial health moving forward. Investors may want to approach with caution until there are signs of improvement in profitability and operational metrics.

Should I buy, sell or hold Rossari Biotech Ltd?

Is Rossari Biotech technically bullish or bearish?

As of December 2, 2025, Rossari Biotech's trend is mildly bearish, indicated by bearish MACD and moving averages, mixed RSI signals, and mildly bearish Bollinger Bands, suggesting a cautious outlook.

As of 2 December 2025, the technical trend for Rossari Biotech has changed from bearish to mildly bearish. The current stance is mildly bearish with key indicators driving this assessment being the MACD on both the weekly and monthly time frames, which remain bearish, and the daily moving averages also indicating a bearish trend. The RSI shows a bullish signal on the monthly but no signal on the weekly, suggesting mixed momentum. Bollinger Bands are mildly bearish on both weekly and monthly charts, while KST indicates a mildly bullish stance on the weekly but bearish on the monthly. Overall, the lack of definitive bullish signals and the presence of bearish indicators suggest a cautious outlook.

How has been the historical performance of Rossari Biotech?

Rossari Biotech has demonstrated consistent growth in net sales and profits, with net sales increasing from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, and profit after tax rising from INR 65.47 crore to INR 135.40 crore during the same period. The company's earnings per share improved from INR 12.86 to INR 24.64, reflecting enhanced shareholder value.

Answer:<BR>The historical performance of Rossari Biotech shows a consistent growth trajectory in net sales and profits over the past several years.<BR><BR>Breakdown:<BR>Rossari Biotech's net sales have increased significantly from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, reflecting a robust annual growth trend. The total operating income followed a similar pattern, rising from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025. The company's operating profit (PBDIT) also demonstrated a positive trend, growing from INR 108.46 crore in March 2020 to INR 269.08 crore in March 2025. Profit before tax increased from INR 88.06 crore in March 2020 to INR 184.21 crore in March 2025, while profit after tax rose from INR 65.47 crore to INR 135.40 crore during the same period. The earnings per share (EPS) improved from INR 12.86 in March 2020 to INR 24.64 in March 2025, indicating enhanced shareholder value. On the balance sheet, total assets grew from INR 471.46 crore in March 2020 to INR 1,885.67 crore in March 2025, with total liabilities increasing from INR 471.46 crore to INR 1,885.67 crore as well. The cash flow from operating activities saw a notable rise from INR 56 crore in March 2020 to INR 137 crore in March 2025, while the net cash inflow turned positive at INR 19 crore in March 2025, compared to a negative outflow in previous years. Overall, Rossari Biotech has shown strong financial performance and growth across multiple metrics over the years.

When is the next results date for Rossari Biotech?

Rossari Biotech will announce its results on 15 October 2025.

Rossari Biotech will declare its results on 15 October 2025.

Who are the top shareholders of the Rossari Biotech?

The top shareholders of Rossari Biotech include promoter Edward Menezes with 29.11%, mutual funds holding 13.42%, foreign institutional investors at 3.48%, and individual investors owning 9.44%. The largest public shareholder is Uti-flexi Cap Fund with 6.04%.

The top shareholders of Rossari Biotech include the promoters, who hold the majority of the shares. Edward Menezes is the promoter with the highest holding at 29.11%. Additionally, mutual funds collectively hold 13.42% of the shares across 8 schemes, while foreign institutional investors (FIIs) hold 3.48% through 52 different entities. The highest public shareholder is Uti-flexi Cap Fund, which holds 6.04%. Individual investors collectively own 9.44% of the company.

Is Rossari Biotech overvalued or undervalued?

As of May 21, 2025, Rossari Biotech is considered very attractive and undervalued, with a PE ratio of 27.86, an EV to EBITDA of 14.73, and a ROCE of 15.36%, despite a year-to-date return of -12.35% compared to the Sensex's 5.58%.

As of 21 May 2025, the valuation grade for Rossari Biotech has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 27.86, an EV to EBITDA of 14.73, and a ROCE of 15.36%. <BR><BR>In comparison to its peers, Rossari Biotech's PE ratio is similar to that of its closest competitor, which also shows a PE of approximately 27.86, while the industry average EV to EBITDA is lower, suggesting that Rossari may have a competitive edge in profitability. Despite recent underperformance relative to the Sensex, with a year-to-date return of -12.35% compared to the Sensex's 5.58%, the company's strong fundamentals and attractive valuation metrics support the conclusion that it is undervalued in the current market.

Has Rossari Biotech declared dividend?

Yes, Rossari Biotech Ltd has declared a 25% dividend, amounting to ₹0.5 per share, with an ex-date of August 16, 2024. However, the company's total returns over various periods have been largely negative, particularly in the longer term.

Rossari Biotech Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.5<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.15%, with no dividend return, resulting in a total return of -16.15%.<BR><BR>Over the past year, the price return was 1.18%, with a dividend return of 0.07%, leading to a total return of 1.25%.<BR><BR>In the 2-year period, the price return was -14.66%, with a dividend return of 0.06%, resulting in a total return of -14.6%.<BR><BR>For the 3-year period, the price return was -22.58%, with a dividend return of 0.17%, leading to a total return of -22.41%.<BR><BR>In the 4-year period, the price return was -45.59%, with a dividend return of 0.16%, resulting in a total return of -45.43%.<BR><BR>Over the last 5 years, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Rossari Biotech has declared a dividend, the total returns over various periods indicate a challenging performance, particularly in longer time frames, with significant negative price returns.